Drug Profile

PepGNP ChikV

Alternative Names: Chikungunya vaccine - Gylden Pharma; PepGNP-ChikV

Latest Information Update: 22 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Emergex Vaccines
Developer Gylden Pharma
Class Peptide vaccines; Synthetic vaccines; Viral vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Chikungunya virus infections

Most Recent Events

22 Aug 2025 Preclinical development for Chikungunya virus infections (Prevention) is ongoing in United Kingdom (Transdermal) (Gylden Pharma pipeline, August 2025)
17 Oct 2024 Emergex Vaccines is now called Gylden Pharma
17 Nov 2023 Emergex vaccines intends to submit a regulatory application to MHRA for a phase I trial in Chikungunya virus infections (Prevention) in United Kingdom

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com